The RNA inhibitor olpasiran significantly reduces a type of “bad cholesterol” that’s associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a Phase II trial.
Clinical trial finds RNA inhibitor effectively reduces ‘bad cholesterol’ in patients with cardiovascular disease
